The introduction of nicotinamide being a nicotine replacement in e-cigarette and smokeless goods represents an important regulatory challenge to the FDA. Nicotinamide does not have nicotinic receptor agonist activity and is thought to act as a sedative at higher dosages6. The statements produced by Nicotine River, ECBlend, together with other distr